Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma

[1]  J. Blay,et al.  The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments , 2020, Expert review of anticancer therapy.

[2]  Funda Meric-Bernstam,et al.  Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. , 2020, Cancer discovery.

[3]  T. Kondo,et al.  Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma , 2020, Human Cell.

[4]  Ian O. Ellis,et al.  The 2019 WHO classification of tumours of the breast , 2020 .

[5]  The UniProt Consortium,et al.  UniProt: a worldwide hub of protein knowledge , 2018, Nucleic Acids Res..

[6]  T. Kondo,et al.  Current status of cancer proteogenomics: a brief introduction , 2019, Journal of Electrophoresis.

[7]  Amos Bairoch,et al.  The Cellosaurus, a Cell-Line Knowledge Resource. , 2018, Journal of biomolecular techniques : JBT.

[8]  J. Chezal,et al.  Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing , 2017, PloS one.

[9]  Robin L. Jones,et al.  Phase III Soft Tissue Sarcoma Trials: Success or Failure? , 2017, Current Treatment Options in Oncology.

[10]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[11]  G. Devi,et al.  Three-dimensional culture systems in cancer research: Focus on tumor spheroid model. , 2016, Pharmacology & therapeutics.

[12]  A. Monks,et al.  Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression , 2015, Molecular Cancer Therapeutics.

[13]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[14]  B. Bui,et al.  Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[16]  D. Nguyen,et al.  Cell lineage specification in tumor progression and metastasis. , 2011, Discovery medicine.

[17]  C. Cole,et al.  COSMIC: the catalogue of somatic mutations in cancer , 2011, Genome Biology.

[18]  Nicholas H Oberlies,et al.  Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma , 2011, The Journal of Antibiotics.

[19]  Derek Y. Chiang,et al.  Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy , 2010, Nature Genetics.

[20]  D. Haber,et al.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.

[21]  W. Kamps,et al.  Kinome profiling in pediatric brain tumors as a new approach for target discovery. , 2009, Cancer research.

[22]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[23]  C. Sander,et al.  Functional Copy-Number Alterations in Cancer , 2008, PloS one.

[24]  E. S. Venkatraman,et al.  A faster circular binary segmentation algorithm for the analysis of array CGH data , 2007, Bioinform..

[25]  J. Blay,et al.  Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis , 2006, International journal of cancer.

[26]  Jane Fridlyand,et al.  Bioinformatics Original Paper a Comparison Study: Applying Segmentation to Array Cgh Data for Downstream Analyses , 2022 .

[27]  H. Taubert,et al.  Gains of 13q are correlated with a poor prognosis in liposarcoma , 2005, Modern Pathology.

[28]  O. Mariani,et al.  Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances , 2005, Laboratory Investigation.

[29]  C. Fletcher,et al.  Pleomorphic Liposarcoma: Clinicopathologic Analysis of 57 Cases , 2004, The American journal of surgical pathology.

[30]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[31]  T. Davidson,et al.  Pharmacology, pharmacokinetics, and practical applications of bortezomib. , 2004, Oncology.

[32]  E. Venkatraman,et al.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Eils,et al.  Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. , 2002, Cancer research.

[34]  P. Terrier,et al.  Pleomorphic Liposarcoma: Clinicopathologic, Immunohistochemical, and Follow-up Analysis of 63 Cases: A Study From the French Federation of Cancer Centers Sarcoma Group , 2002, The American journal of surgical pathology.

[35]  M. Wabitsch,et al.  LiSa‐2, a novel human liposarcoma cell line with a high capacity for terminal adipose differentiation , 2000, International journal of cancer.

[36]  C. Bokemeyer,et al.  Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience , 1999, Oncology.

[37]  R. Schneider-Stock,et al.  MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas , 1998, Journal of Cancer Research and Clinical Oncology.

[38]  A. Billiau,et al.  Human Interferon: Mass Production in a Newly Established Cell Line, MG-63 , 1977, Antimicrobial Agents and Chemotherapy.

[39]  D. Starling.  Two ultrastructurally distinct tubulin paracrystals induced in sea-urchin eggs by vinblastine sulphate. , 1976, Journal of cell science.